Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels
Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.
You may also be interested in...
With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.
Regeneron is partnering with the troubled ophthalmology-focused biotech to develop a sustained-release formulation of Eylea that could enable a less-frequent dosing regimen.
The FDA approval for idiopathic OAB follows a narrower indication for OAB related to neurological diseases such as multiple sclerosis or spinal cord injury.